Evidence map›Paper›PMID 41217577›Full record

ArticleMolecular neurobiology2025

Neural Stem Cell-conditioned Medium Protected Against Cognitive Dysfunction in APP/PS1 Mice.

Xiaoyu Zheng, Qian Xiang, Xiaoxu Dong, Yang Shen, Tingyu Qu, Wei Fang, Hongna Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoyu ZhengDepartment of Critical-Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, China.
Qian XiangDepartment of Critical-Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, China.
Xiaoxu DongDepartment of Critical-Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, China.
Yang ShenDepartment of Critical-Care Medicine, Shandong Province Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, China.
Tingyu QuDepartment of Psychiatry, College of Medicine, The Psychiatric Institute, University of Illinois at Chicago, 1601 West Taylor Street, Chicago, IL, 60612, USA.
Wei FangDepartment of Critical-Care Medicine, Shandong Province Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, China.
Hongna YangDepartment of Critical-Care Medicine, Shandong Provincial Hospital, Shandong University, Jinan, China. 7216263@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More and more evidence suggested neural stem cell conditioned medium (NSC-CM) exhibited a protective effect on regenerative medicine. Our previous studies suggested that NSC-CM ameliorated Aβ2-35-induced SH-SY5Y cell apoptosis as the cell model of Alzheimer's disease (AD). Thus, we hypothesized that NSC-CM had the capacity of neuro-protecting against cognitive dysfunction in APP/PS1 mice. Male APP/PS1 mice aged 6 months as the animal model of AD were randomly assigned into two groups: the control group and NSC-CM treated group. A 100 μl NSC-CM or PBS (phosphate-buffered saline) was administered slowly by tail vein once a day for consecutive 7 days or 14 days. The new object recognition test (NORT) and open field test (OFT) were applied to test cognition and emotion. The levels of phosphorylated tau (p-Tau), NOD-like receptor family pyrin domain-containing 3 (NLRP3), caspase-1, and interleukin 1β (IL-1β) were measured by Western blot. The load of amyloid-β (Aβ) plaque was measured by thioflavin S staining while the expression of astrocytes was observed by immunofluorescence staining. NSC-CM not only significantly ameliorated cognitive and emotional dysfunctions of APP/PS1 transgenic mice but also reduced the Aβ plaque load as well as the level of p-Tau, accompanied by increased astrocyte phagocytosis and inhibiting the inflammatory activation of astrocytes as well as the levels of NLRP3, caspase-1, and IL-1β. NSC-CM might be the alternative and promising therapeutic intervention for treating AD.

Indexed as

Amyloid beta-Protein PrecursorCognitive DysfunctionNeural Stem CellsPresenilin-1Alzheimer DiseaseAmyloid beta-PeptidesAnimalsAstrocytesCaspase 1Culture Media, ConditionedDisease Models, AnimalInterleukin-1betaMaleMiceMice, TransgenicNLR Family, Pyrin Domain-Containing 3 ProteinAmyloid beta-PeptidesAmyloid beta-Protein PrecursorCaspase 1Culture Media, ConditionedInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinPresenilin-1tau ProteinsAlzheimer’s diseaseAstrocytesCognitive dysfunctionNeural stem cell–conditioned mediumNLRP3Phosphorylation Tau protein

Identifiers

PMID41217577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.